Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy

被引：196

作者：

Klos, KJ ^{[1
]}

Bower, JH ^{[1
]}

Josephs, KA ^{[1
]}

Matsumoto, JY ^{[1
]}

Ahskog, JE ^{[1
]}

机构：

[1] Mayo Clin, Div Movement Disorders, Dept Neurol, Rochester, MN 55905 USA

来源：

PARKINSONISM & RELATED DISORDERS | 2005年 / 11卷 / 06期

关键词：

hypersexuality; Parkinson's disease; parkinsonism; multiple system atrophy;

D O I：

10.1016/j.parkreldis.2005.06.005

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Pathological hypersexuality developed in 13 patients with PD and two patients ultimately diagnosed clinically with MSA. Hypersexuality began within 8 months after starting dopamine agonist therapy in 14 of 15 cases, including four on agonist monotherapy. It resolved in the four cases where the agonist was stopped, despite continued levodopa therapy. This was not an isolated behavioral problem in most, with additional compulsive or addictive behaviors coinciding in nine patients (60%). A systematic literature review of pathological hypersexuality in PD revealed similar medication histories; combining these cases with our series, 26 of 29 patients (90%) were on adjuvant dopamine agonists. (c) 2005 Elsevier Ltd. All rights reserved.

引用

页码：381 / 386

页数：6

共 13 条

[1] Clozapine for dopaminergic-induced paraphilias in Parkinson's disease [J].

Fernandez, HH ;

Durso, R .

MOVEMENT DISORDERS, 1998, 13 (03) :597-598

[2] Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum [J].

Gerlach, M ;

Double, K ;

Arzberger, T ;

Leblhuber, F ;

Tatschner, T ;

Riederer, P .

JOURNAL OF NEURAL TRANSMISSION, 2003, 110 (10) :1119-1127

[3]

Gilman S, 1999, Neurologia, V14, P425

[4] Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies [J].

Giovannoni, G ;

O'Sullivan, JD ;

Turner, K ;

Manson, AJ ;

Lees, AJL .

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2000, 68 (04) :423-428

[5]

Jiménez-Jiménez FJ, 2002, ANN PHARMACOTHER, V36, P1178

[6]

Kaplan H., 1994, Synopsis of psychiatry, V7th

[7]

Levant B, 1997, PHARMACOL REV, V49, P231

[8]

Low PA., 1997, CLIN AUTONOMIC DISOR, P555

[9] LOCALIZATION OF DOPAMINE D-3 RECEPTORS TO MESOLIMBIC AND D-2 RECEPTORS TO MESOSTRIATAL REGIONS OF HUMAN FOREBRAIN [J].

MURRAY, AM ;

RYOO, HL ;

GUREVICH, E ;

JOYCE, JN .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (23) :11271-11275

[10] Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D1, D2 and D3 receptors [J].

Perachon, S ;

Schwartz, JC ;

Sokoloff, P .

EUROPEAN JOURNAL OF PHARMACOLOGY, 1999, 366 (2-3) :293-300

← 1 2 →